Memantine Vipharm (Memantine Hydrochloride)

Memantine blocks the NMDA‑type glutamate receptors in a non‑competitive manner, preventing excessive calcium entry that can cause neuronal damage. This modulation reduces excitotoxicity while allowing normal synaptic activity, supporting neuronal health in Alzheimer’s disease.

The dosage of Memantine Vipharm is determined by the prescribing clinician based on the patient’s condition, renal function, and treatment response. The prescriber will set the appropriate dose and titration schedule.

Safety of memantine in pregnancy or while breastfeeding has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Memantine Vipharm, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA‑receptor antagonist class, whereas other approved agents such as donepezil, rivastigmine and galantamine are acetylcholinesterase inhibitors. Memantine targets excitotoxic pathways, offering a different mechanism that can be used alone or in combination with cholinesterase inhibitors for broader symptom control.

Memantine Vipharm should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct light to maintain stability throughout its shelf life.

Memantine Vipharm is taken orally, usually as a tablet swallowed with water. The exact administration schedule, including any dose titration, is determined by the prescribing physician.

Serious risks include the potential for seizures, cardiac arrhythmias, severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome, and hepatic dysfunction. Patients should be monitored for these events, especially if they have pre‑existing risk factors.

Memantine Vipharm is contraindicated in patients with known hypersensitivity to memantine or any of its excipients. Caution is also advised for individuals with severe renal impairment, uncontrolled epilepsy, or those taking other NMDA antagonists.